SCHOTT Pharma with positive start to financial year 2026; outlook confirmed

• Revenue increase in Q1 2026 by 4.8% at constant currencies to EUR 240.2 million (reported: 3.8%)
• EBITDA margin was 27.1% (Q1 2025: 25.4%)
• Share of high‑value solutions (HVS) remains high at 57%, on par with the strong result of the 2025 financial year (Q1 2025: 55%)
• Outlook for the 2026 financial year confirmed

SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, has made a positive start to the 2026 financial year. Revenue in the first quarter (Oct 1, 2025 – Dec 31, 2025) increased by 4.8% at constant currencies to EUR 240.2 million. On a reported basis, revenue grew by 3.8%. EBITDA amounted to EUR 65.2 million, representing a significant increase of 11.1%. The corresponding EBITDA margin reached 27.1% (Q1 2025: 25.4%).

“We are very pleased with our start to the 2026 financial year,” said Andreas Reisse, CEO of SCHOTT Pharma. “The first quarter performed slightly better than originally expected in terms of both revenue and earnings. Increased demand was visible across our portfolio, with the need for our high‑margin high-value solutions remaining strong. With HVS accounting for 57% of sales, we were able to build on the very good level achieved in the previous financial year. Despite ongoing uncertainties, we remain optimistic about the current financial year and confirm our revenue and earnings guidance for 2026.”

Reinhard Mayer, CFO of SCHOTT Pharma, added: “With our strategy focused on high‑value solutions, we once again achieved a very good profitability. This reinforces our decision to continue expanding our capacities in this area to meet the rising demand for sophisticated drug containment solutions and delivery systems.”

Profitable growth driven by high‑value solutions in DCS

The Drug Containment Solutions (DCS) segment, which includes glass vials, ampoules, and cartridges for storing injectable drugs, was the main driver of the positive development. With continued strong demand for sterile cartridges and specialty vials, the segment generated revenue of EUR 137.2 million, an increase of 9.4% at constant currencies (reported: 6.9%). HVS continued to perform very well, reaching a revenue share of 24%. EBITDA grew significantly by 18.9% to EUR 33.4 million, with volume and product‑mix effects more than offsetting ramp‑up costs linked to capacity relocations. The EBITDA margin rose to 24.3%, compared with 21.9% in the first quarter of 2025.

The Drug Delivery Systems (DDS) segment consists of glass and polymer syringes and therefore solely of HVS. With revenues of EUR 103.1 million, the segment remained at the level of the prior‑year quarter. At constant currencies, the development was slightly negative at –0.8%. Demand for prefillable glass syringes—particularly for GLP‑1—remained high, while the reduced use of mRNA vaccines continued to have a dampening effect on polymer syringes. EBITDA in the segment declined by –7.3% to EUR 32.6 million, in line with expectations. The main reasons were product‑mix effects, lower production utilization for polymer syringes, and ramp‑up costs for new glass‑syringe capacities in Hungary. The EBITDA margin was 31.6% (Q1 2025: 34.1%).

Continuation of growth investments

Cash flow from operating activities amounted to EUR 3.4 million, significantly below the prior‑year level of EUR 25.1 million. This was primarily due to a change in working capital, largely driven by a deferred payment by a major customer at the end of the quarter. Adjusting for this effect, operating cash flow would have remained at prior-year level.

SCHOTT Pharma continued to invest in the expansion of its capacities in the first quarter of 2026, particularly for HVS. The focus was on sites in Switzerland and Hungary. Capital expenditure (CAPEX) amounted to EUR 23.4 million, slightly above the prior‑year level.

Addressing market trends

In developing new products, SCHOTT Pharma focuses on addressing and advancing global industry trends. The company has expanded its portfolio of large‑volume syringes and cartridges, which can be integrated into autoinjectors from cooperation partners, enabling patients to self‑administer highly sensitive biologic drugs.

Specifically for the safe lyophilization and storage of light‑sensitive antibody‑drug conjugates (ADCs), SCHOTT Pharma has launched EVERIC® lyo & amber in January—innovative vials that meet regulatory requirements in the EU, the US, and Japan.

Outlook confirmed

SCHOTT Pharma confirms the forecast published in December for the 2026 financial year, which expects revenue growth at constant currencies of 2–5% and an EBITDA margin of around 27%.

Further news about SCHOTT Pharma can be found in the Media Center.

Webcast

CEO Andreas Reisse and CFO Reinhard Mayer will present the Q1 2026 results during a conference call for analysts and investors on February 11, 2026 at 11:00 a.m. CET. The audio webcast can be accessed via the following link. The accompanying presentation is available on the Investor Relations website at https://www.schott-pharma.com/investor-relations

About SCHOTT Pharma 

Human health matters. That is why SCHOTT Pharma designs containment solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 986 million in the financial year 2025. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Further information at www.schott-pharma.com

Media contact

Katrin Schreyer

Global Communications Manager

Tel.: +49 (0) 171 116 7544

E-Mail: katrin.schreyer@schott.com

Lea Kaiser

PR & Communications Manager

Tel.: +49 (0) 151 6891 7195

E-Mail: lea.kaiser@schott.com

Investor Relations contact

Tobias Erfurth

Head of Investor Relations

Jasko Terzic

Senior Manager Investor Relations

E-Mail: ir.pharma@schott.com

Q1 2025/26 (October – December 2025)

DOUGLAS Group delivers solid performance amid challenging market and economic environment

• Preliminary Q1 figures confirmed: Sales grew by 1.7% to 1.67 billion euros; adjusted EBITDA of 333.7 million euros, representing an adj. EBITDA margin of 19.9%.
• Market environment: Premium beauty market continues to grow, albeit at a slower pace; ongoing geopolitical and macroeconomic developments weigh on consumer confidence and increase price sensitivity, leading to notable volatility across markets and time periods.
• E-Com momentum: Online business, including high-performing cross-channel services and strong partner program, continues to lead growth.
• Financials: Significantly reduced net financial debt and continued strict cost management.
• FY 2025/26 guidance unchanged: Sales of 4.65-4.80 billion euros and an adj. EBITDA margin of around 16.5%; net leverage between 2.5x and 3.0x as of 30 September 2026.

Düsseldorf, 11 February, 2026 – Amid an ongoing challenging economic environment, the DOUGLAS Group demonstrates resilience by maintaining its strong market position with a total sales increase of 1.7% in the first quarter of the financial year 2025/26. The period from October to December 2025 was characterized by sales volatility across channels and markets, driven by consumer uncertainty and heightened price sensitivity – factors largely influenced by broader macroeconomic and geopolitical developments. These dynamics led to a more selective spending behavior of customers and to a promotion-driven demand in the market, exerting pressure on gross margins and resulting in an adjusted EBITDA margin of 19.9% (PY: 21.5%).

Sander van der Laan, CEO DOUGLAS Group, said: “The market in which we operate continues to grow and we maintain our strong position. However, with consumers currently thinking twice about spending, competition has gotten tougher, and price promotions have become more important for all players in the market. As a result of this development, market growth has slowed down across the board, with a flat development in our largest markets Germany and France mitigating the growth of other markets. That said, our business model remains highly profitable, and we’re in an excellent position to benefit once the market regains pace. Our USP lies not only in the unique integration of retail stores and cutting-edge E-Com, but also in the exclusivity of our product range and service offering. We will develop and expand our range and expect it to provide further growth momentum.“

E-Com momentum and strong CEE performance

Sales performance varied across segments and channels throughout the quarter. Central Eastern Europe delivered a strong result with overall growth of 7.3%. Sales in the generally weaker French market climbed by 1.2%, while the DACHNL segment saw an increase of 0.6%. Supported by the network expansion, store sales grew 0.4% (like-for-like, “lfl”: -2.8%) compared to the prior-year period, whereas the Group’s E-Com business rose 4.2% year-on-year. E-Com momentum was also  fueled by cross-channel services, including Click and Collect Express, which continue to enjoy high demand from customers and grew double-digit – underlining the attractiveness of omnichannel in beauty retail. The partner program has similarly developed well and grew strongly year-on-year.

The DOUGLAS Group continues to enhance its digital presence and business model for the future and with a clear focus on profitability. Beyond the strong net order intake increase, the partner program also saw a sharp rise in the number of unique partners while maintaining high curation standards in line with the overarching assortment strategy. The highly profitable Retail Media unit DOUGLAS Marketing Solutions also kept its growth trajectory with double-digit growth in both sales and earnings, reflecting a strong demand for its tailored marketing and data offerings during the peak season on one of Europe’s leading online platforms for premium beauty.

Serving as a connector between channels, the DOUGLAS App again demonstrated its important role in the Group’s business, with more than every third E-Com purchase made through the app.

Profitability impacted by pressure on gross margin

Uncertainty and price sensitivity among consumers, leading to the aforementioned intensified promotional activity throughout the market both in stores and E-Com, continued to weigh on the gross margin during the first quarter and affected overall profitability. Cost control measures to safeguard profitability were offset by temporary margin dilution due to ramp-up effects of new stores performance. Adjusted EBITDA decreased by 5.6% to 333.7 million euros, resulting in a margin of 19.9% (PY: 21.5%). Net leverage was 2.6x as of 31 December 2025 (31 December 2024: 2.3x), or 1.4x before leases.

Despite the lower adj. EBITDA, increased average inventory levels mainly due to store openings, as well as higher investments in the store network and IT infrastructure, the free cash flow remained strong with 464.4 million euros compared to 494.5 million euros in Q1 2024/25. The financial result in the quarter improved by around 5 million euros thanks to lower interest charges reflecting the continuous financial deleveraging, with net financial debt (excluding leases) reduced by more than 180 million euros to now 609 million euros.

High customer demand on Black Friday

The DOUGLAS Group and its retail brands experienced high customer demand during the sales highlight Black Friday in November: Web traffic on the DOUGLAS and NOCIBÉ online shops soared to more than 3.5 times the volume of regular Fridays, and demand peaked at approximately 25,000 orders per hour. On that day alone, the company processed nearly 358,000 orders across its 22 omnichannel markets. Notably, in Germany, the DOUGLAS App secured the number one spot among shopping apps in the iOS App Charts.

However, while key promotional events like Singles’ Day and Black Week proved highly attractive to customer, they also partially pulled forward demand originally expected for the Christmas business.

Sander van der Laan: “Following the post-pandemic upswing, the European premium beauty market is now facing headwinds from a variety of external factors. Geopolitical tensions, trade conflicts, and the rising cost of living have triggered consumer caution across the retail sector, especially in Germany, France and the Netherlands. Nevertheless, we delivered a solid performance as Europe’s leading premium beauty retailer. We remain focused on and fully confident in our strengths, such as our unique integration of retail stores and cutting-edge E-Com, our unrivaled assortment backed by exceptional brand power, as well as our loyal and growing customer base and highly motivated workforce.”

Development of assortment, store network and harmonization of IT landscape

Underscoring its ambition to offer customers the most relevant and distinctive range of brands in beauty retail, the Group is developing its assortment towards exclusivity as a key differentiator. In January, it has soft-launched the make-up brand about-face by world famous singer Halsey in online shops, with a full omnichannel rollout set for March 2026. Furthermore, it will launch the fragrance brand Orebella from famous model Bella Hadid at the end of February. Both are key exclusive launches in the financial year 2025/26 that set the DOUGLAS Group apart as the best place to shop.

As an integral part of its omnichannel strategy, the company continued developing its store network and opened 13 new own stores (net) between October and December 2025, bringing the total number of stores up to 1,972 (including franchise). Highlights included a flagship store in Cologne, Germany, on the Schildergasse, one of Europe’s most visited shopping streets, as well as the 170th store in Poland (Zawiercie). 22 stores were refurbished in the same period (including relocations).

To ensure its future-readiness, the DOUGLAS Group is harmonizing its IT landscape across the entire Group. Over the course of the last two years, it has already reached significant milestones in this multi-year transformation program and successfully completed twelve rollouts and four omnichannel warehouse integrations. As of today, ten out of 22 countries are operating on the full Group tech stack, with more to follow throughout 2026 and the coming years. Similarly, the Group has made strong progress in harmonizing its payment operations across countries and channels, which will bring cost benefits as well as an improved customer experience due to better credit card acceptance.

Guidance for 2025/26 remains unchanged

The full-year guidance remains unchanged, with expected sales between 4.65 and 4.80 billion euros, an adj. EBITDA margin of approximately 16.5%, and net leverage between 2.5x and 3.0x as of 30 September 2026.

On 26 February, the DOUGLAS Group will host its Annual General Meeting. Details on this year’s AGM, which will again be held in a virtual setting, are available on the DOUGLAS Group website.

Overview Financial Results (Q1 2025/26)

1. Sales per channel

2. Sales per segment

3. Key financial figures

Segment Overview: DACHNL (Austria, Belgium, Germany, Switzerland, The Netherlands), France (France, Monaco), SE / Southern Europe (Andorra, Croatia, Italy, Portugal, Slovenia, Spain), CEE / Central Eastern Europe (Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia), PD/NB (Parfumdreams, Niche Beauty)

X-Channel refers to cross-channel services (Click & Collect, Click & Collect Express, in-store orders)

About the DOUGLAS Group

The DOUGLAS Group, with its commercial brands DOUGLAS, NOCIBÉ, Parfumdreams and Niche Beauty, is the number one omnichannel premium beauty destination in Europe. The DOUGLAS Group is inspiring customers to live their own kind of beauty by offering a unique assortment online and in around 1,970 stores. With unparalleled size and access to customers, the DOUGLAS Group is the partner of choice for brands and offers a premium range of selective and exclusive brands as well as own corporate brands. The assortment includes fragrances, color cosmetics, skin care, hair care, accessories as well as beauty services. Strengthening its successful omnichannel positioning while consistently developing superior customer experience is at the heart of the DOUGLAS Group strategy “Let it Bloom”. The winning business model is underpinned by the Group’s omnichannel proposition, leading brands, and data capabilities. In the financial year 2024/25, the DOUGLAS Group generated sales of 4.58 billion euros and employed more than 19,900 people across Europe. The DOUGLAS Group (Douglas AG) is listed at the Frankfurt Stock Exchange.

For further information please visit the DOUGLAS Group Website.

Press Contact

Peter Wübben
SVP Group Communications & Sustainability
Phone: +49 211 16847 6644
Mail: newsroom@douglas.de

Investor Contact

Dafne Sanac
Director / Senior Principal Investor Relations
Phone: +49 151 55675545
Mail: ir@douglas.de

Press Release // February 11, 2026
 

Lotus Pharmaceutical becomes commercialization partner for Formycon’s Keytruda^® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region
 

Planegg-Martinsried, Germany and Taipei, Taiwan – Formycon AG (FSE: FYB, “Formycon”) and Lotus Pharmaceutical (“Lotus”) today announced the conclusion of an exclusive license agreement for Formycon’s Keytruda^®1 biosimilar candidate FYB206 (Pembrolizumab). Lotus, a multinational pharmaceutical company with a strong presence in Asia and a diverse portfolio of novel, generic and biosimilar medicines will commercialize FYB206 across major parts of the Asia-Pacific (“APAC”) Region. 

Upon signature of the agreement, Formycon will receive an upfront payment and will be eligible for further payments contingent on the achievement of certain development and regulatory milestones. In addition, Formycon will receive a share of the gross profits upon market launch in the region and will be responsible for the manufacturing and supply of the finished product.

“The addition of this important oncology therapeutic to our existing partnership with Lotus underscores our well-established and trusted collaboration and marks another important step in Formycon’s global commercialization strategy. Lotus has a unique footprint in the APAC region. Together we aim to broaden patient access to effective and cost‑efficient treatment options for serious diseases while creating sustainable long-term value”, said Nicola Mikulcik, CBO of Formycon AG.

Petar Vazharov, CEO of Lotus Pharmaceutical, commented: “We are pleased to expand our collaboration with Formycon through this agreement for FYB206, a highly important biosimilar candidate in oncology. Biosimilars represent a key growth pillar for Lotus, and pembrolizumab is among the most clinically impactful and widely used biologics globally. By combining Formycon’s development expertise with Lotus’ strong commercial platform across Asia-Pacific, we aim to improve patient access to high-quality, cost-effective biologic therapies while further strengthening our specialty oncology portfolio in the region.”

FYB206 is approaching the end of its clinical development phase, with primary endpoint data expected in the first quarter of 2026. Following completion of the data package, Formycon and Lotus will closely align to prepare the regulatory submissions in the APAC countries according to the local requirements.

Pembrolizumab is a humanized monoclonal antibody that belongs to the group of immune checkpoint inhibitors and is used to treat a variety of tumors. With its broad range of indications in oncology and global sales of US$ 31.7 billion in 2025², Keytruda^® is currently one of the world’s best-selling drugs, underscoring the substantial oncology demand and market potential across the world. According to market research estimates, sales in the Asia-Pacific region could amount to approximately $7.0 billion in 2025³.

—————

¹   Keytruda® is a registered trademark of Merck Sharp & Dohme LLC, 
     a subsidiary of Merck & Co, Inc, Rahway, NJ/USA

²   https://www.merck.com/news/merck-highlights-progress-advancing-broad-diverse-pipeline/

³   https://www.grandviewresearch.com/horizon/outlook/keytruda-market/asia-pacific

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/ranibizumab and FYB202/ustekinumab, Formycon already has two biosimilars on the market. Another biosimilar, FYB203/aflibercept, has been approved by the FDA, EMA, and MHRA. Four pipeline candidates – including FYB208/dupilumab – are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines.

Formycon AG is headquartered in Munich and listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY. Further information can be found at: https://www.formycon.com/

About Lotus
Founded in 1966, Lotus (1795: TT) is a global pharmaceutical company focused on novel and generic drugs, providing better, safer, and more accessible medicines. With a top-tier R&D and manufacturing platform in Asia, Lotus has partnerships in major markets including the U.S., Europe, Japan, China, and Brazil. The company manages over 100 strategic projects in Asia and the US, with a portfolio exceeding 250 commercial products. Lotus invests in a diverse portfolio of high-barrier oncology treatments, complex generics, 505(b)(2), and NCE drugs through internal R&D and licensing. It also strengthens its competitiveness with biosimilars, supported by strategic partners. Its infrastructure is certified by leading regulatory authorities, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Further information can be found at https://www.lotuspharm.com/

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare systems. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

Contact:
Sabrina Müller 
Director Investor Relations and  
Corporate Communications
Formycon AG 
Fraunhoferstr. 15
82152 Martinsried/Planegg  
Germany  

Phone +49 (0) 89 – 86 46 67 149
Fax + 49 (0) 89 – 86 46 67 110 
Sabrina.Mueller@formycon.com  

Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.

Gerresheimer AG reschedules publication of annual and consolidated financial statements for 2025 and initiates sale of Centor Inc.

Duesseldorf, February 10, 2026. The Management Board of Gerresheimer AG (ISIN: DE000A0LD6E6,“Gerresheimer”) today decided to defer the publication of the 2025 annual and consolidated financial statements, originally scheduled for February 26, 2026.

Based on internal indications and in consultation with the auditor, Gerresheimer commissioned further investigations by a second auditing firm to examine revenue recognition and accounting practices in the 2024 and 2025 financial years. With these newly initiated investigations, the company aims to ensure that the previous year’s figures are comprehensively corrected, taking into account the findings of the investigation by an independent external law firm in connection with the ongoing BaFin proceedings, and that the annual and consolidated financial statements for the financial year 2025 fully meet the requirements for quality, conformity and transparency.

As the investigations are still ongoing, more time is needed to prepare and audit the 2025 annual and consolidated financial statements, including the correction of the previous year’s figures. A new publication date will be set in consultation with the auditor.

According to the findings to date, the new investigations initiated by Gerresheimer indicate that individual employees have violated internal guidelines and IFRS regulations. The resulting corrections of the consolidated financial statements mainly relate to the recognition of revenues and the accounting and valuation of inventories. The company continues to investigate the causes and responsibilities and has already taken personnel and organizational measures.

Based on the current findings of the ongoing investigations and the current preparation status of the annual statements, Gerresheimer currently expects additional adjustments to be necessary for the 2024 financial year. These are expected to decrease revenues by around EUR -17 million and around EUR -19 million in adjusted EBITDA, including around EUR -4 million in earnings impact from the valuation of inventories. Including the previously announced corrections to revenues from bill and hold agreements, this results in an expected correction requirement of around EUR -35 million for revenue recognition and around EUR -24 million for adjusted EBITDA for the financial year 2024. The incorrect entries from financial year 2025 identified during the ongoing investigations will be corrected.

The corrections will have an impact on the forecast for financial year 2025 which was last updated October 2025. 
Based on the current preparation status of the annual statements and considering the findings of the ongoing investigations, the decrease in revenues in 2025 is expected to be at the upper end of the forecast range of -4% to -2% or slightly better. The adjusted EBITDA margin is expected to be between 16.5% and 17.5% in financial year 2025 (previously 18.5% to 19.0%). Adjusted EPS is expected to decrease in the high double-digit percentage range and may even turn negative (previously: decrease in the mid-double-digit percentage range).

Based on the results of the impairment tests available to date, the company expects non-cash impairments of around EUR 220 to 240 million in its consolidated financial statements for the 2025 financial year. These mainly relate to impairments of technology and development projects of Sensile Medical AG, Olten, Switzerland, and, among others, impairment losses to the assets of Gerresheimer Moulded Glass Chicago Inc., Chicago, USA. The Moulded Glass plant in Chicago Heights will be closed at the end of financial year 2026 as one of the measures of the transformation program.

To optimize its capital and financing structure, Gerresheimer has initiated the sale of its wholly owned subsidiary Centor Inc., USA, and plans to complete this transaction before the end of this year. Centor specializes in packaging systems for dispensing prescription drugs in the USA. Gerresheimer has mandated the investment bank Morgan Stanley & Co. International plc to handle this transaction. The separation of the Moulded Glass business is also being further pursued, but the intended subsequent sale process will not be initiated in financial year 2026, but at a later date.

For the 2026 financial year, Gerresheimer expects, before M&A activities, revenues of around EUR 2.3 to 2.4 billion, an adjusted EBITDA margin of around 18 to 19%, and a moderately positive free cash flow, despite an expected weaker first half-year.

End of Inside Information

_______________________

Information and Explanation of the Issuer to this announcement:

Contact Gerresheimer AG

Investor Relations

Guido Pickert
Vice President Investor Relations

T +49 211 6181 220
gerresheimer.ir@gerresheimer.com

Gerresheimer AG reschedules publication of annual and consolidated financial statements for 2025 and initiates sale of Centor Inc.

• Ongoing investigations initiated by the company require more time for the preparation and audit of the annual accounts
• Sale of US subsidiary Centor to optimize capital and financing structure this year
• Transformation program successfully launched
• Outlook for 2026: Revenues of EUR 2.3 to 2.4 billion and moderately positive free cash flow expected

Duesseldorf, February 10, 2026. Gerresheimer AG, an innovative system and solution provider and global partner for the pharma, biotech, and cosmetics industries, is deferring the publication of its 2025 annual and consolidated financial statements. A new publication date will be determined in consultation with the auditor. Based on internal indications and in consultation with the auditor, Gerresheimer has commissioned further investigations by a second auditing firm into the revenue recognition and accounting practices in the 2024 and 2025 financial years. In doing so, the company aims to ensure that the previous year’s figures are comprehensively corrected, taking into account the findings of the investigation by an independent external law firm in connection with the ongoing BaFin proceedings, and that the annual and consolidated financial statements for the financial year 2025 fully meet the qualitative requirements. As the investigations are still ongoing, more time is needed to prepare and audit the 2025 annual and consolidated financial statements, including the correction of the previous year’s figures. In order to optimize its capital and financing structure, Gerresheimer has initiated the sale of its US subsidiary Centor Inc.
Centor specializes in packaging systems for dispensing prescription drugs in the USA. The investment bank Morgan Stanley & Co. International plc has been mandated to handle the transaction. At the same time, Gerresheimer is further pursuing the implementation of its comprehensive transformation program gto in order to lead the company back onto a profitable growth path. For the 2026 financial year, Gerresheimer expects revenues of around EUR 2.3 to 2.4 billion, an adjusted EBITDA margin of around 18 to 19%, and a moderately positive free cash flow. 

“As the newly formed management team, we want to ensure that the 2025 annual and consolidated financial statements fully meet our standards of quality, compliance, and transparency,” said Wolf Lehmann, CFO of Gerresheimer AG. “Due to the ongoing investigations, the process is taking longer than expected. We are working through the issues identified so far in the investigations in a structured manner and in close consultation with the auditor.”

“The focus on partnership-based cooperation with our customers and the consistent implementation of our transformation program will put Gerresheimer back on the road to success,” said Uwe Röhrhoff, CEO of Gerresheimer AG. “The optimization of our capital and financing structure through the planned sale of Centor will enable us to implement the necessary measures and thus leverage the existing potential of our company.”

Investigations are ongoing

Based on internal indications and in consultation with its auditor, Gerresheimer has commissioned further investigations by a second auditing firm to examine revenue recognition and accounting practices in the 2024 and 2025 financial years.

According to the findings to date, the new investigations initiated by the company indicate that individual employees have violated internal guidelines and IFRS requirements. The resulting corrections in the consolidated financial statements mainly relate to the recognition of revenues and the accounting and valuation of inventories Gerresheimer is continuing to investigate the causes and responsibilities and has already taken initial personnel and organizational measures.

Based on the current findings of the ongoing investigations and the current preparation status of the annual statements, including the previously announced corrections to revenues from bill-and-hold agreements, this results in a total expected correction requirement of approximately EUR -35 million for revenue recognition and approximately EUR -24 million for adjusted EBITDA for the 2024 financial year. Incorrect entries from financial year 2025 identified in the ongoing investigations will be corrected.

Impact on the 2025 forecast and expected impairments

Based on the current preparation status of the annual statements and considering the findings of the ongoing investigations, the decrease in revenue in 2025 is expected to be at the upper end of the forecast range of -4% to -2% or slightly better. The adjusted EBITDA margin is expected to be between 16.5 and 17.5% in financial year 2025 (previously 18.5 to 19.0%). Adjusted EPS is expected to decrease in the high double-digit percentage range and may even turn negative (previously: decrease in the mid-double-digit percentage range).

Based on the results of the impairment tests available to date, Gerresheimer expects non-cash impairments of around EUR 220 to 240 million in the consolidated financial statements for the 2025 financial year. These mainly relate to impairments of technology and development projects of Sensile Medical AG and, among others, impairment losses to the assets of Gerresheimer Moulded Glass Chicago Inc., Chicago, USA. The Moulded Glass plant in Chicago Heights will be closed at the end of financial year 2026 as one of the measures of the transformation program.

Sale of Centor to optimize capital and financing structure

Due to strong interest from potential buyers, Gerresheimer has initiated the sale of its wholly owned subsidiary Centor Inc., USA, and plans to complete the transaction before the end of this year. Centor specializes in packaging systems for dispensing prescription drugs in the USA. With the sale, for which the investment bank Morgan Stanley & Co. International plc has already been mandated, the company aims to optimize its capital and financing structure. The separation of the Moulded Glass business is also being further pursued, but the intended subsequent sale process will not be initiated in financial year 2026, but at a later date.

Transformation program gto successfully launched

To put the company on a path to profitable growth, Gerresheimer is currently implementing a comprehensive transformation program aimed at reducing costs, enhancing performance, and improving free cash flow. Among other things, the program includes more selective investment planning, improved working capital management, measures to increase operational and sales performance, the optimization of procurement and the global production network. For example, Gerresheimer will close its Type 1 Moulded Glass plant in Chicago Heights, USA, by the end of the 2026 financial year and transfer the business to its three other Type 1 Moulded Glass plants in Italy and India.

Outlook for 2026: Positive free cash flow

Gerresheimer anticipates a stable to slightly growing market environment for the pharma and cosmetics market in financial year 2026. The company expects, before M&A activities, revenues of around EUR 2.3 to 2.4 billion, an adjusted EBITDA margin of around 18 to 19%, and a moderately positive free cash flow, despite an expected weaker first half-year.

About Gerresheimer
Gerresheimer is an innovative system and solution provider and global partner to the pharmaceutical, biotech, and cosmetics industries. The Group offers a comprehensive portfolio of drug containment solutions, including closures and accessories, as well as drug delivery systems, medical devices, and solutions for the healthcare industry. The range of services includes digital solutions for therapy support, on-body devices, syringes, pens, autoinjectors, and inhalers, as well as vials, cartridges, ampoules, tablet containers, infusion bottles, drip bottles, and syrup bottles. Gerresheimer ensures that drugs reach patients safely and can be administered reliably. Gerresheimer supports its customers with comprehensive services along the value chain and by addressing the growing demand for greater sustainability. With over 40 production sites in 16 countries in Europe, America, and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma 2024, the Group generated sales of around EUR 2.4 billion and currently employs around 13,600 people. Gerresheimer AG is listed on the SDAX index of the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
www.gerresheimer.com

Contact Gerresheimer AG 

CorTec Announces Successful Second Human Implantation of Its Brain-Computer Interface (BCI) System

Second implantation at Harborview Medical Center in Seattle marks continued progress in the FDA-approved study informed by promising results from the first participant.

Freiburg, Germany, February 10, 2026 – CorTec GmbH, a pioneer in active implantable medical technologies, today announced the successful second implantation of its proprietary Brain-Computer Interface (BCI) system, the Brain Interchange™, in an FDA‑approved clinical trial involving stroke patients at Harborview Medical Center, a major site of UW Medicine. The implantation follows encouraging neurological gains observed in the study’s first participant, whose rehabilitation progress has strengthened confidence in CorTec’s fully implantable platform for stroke recovery. This represents another key milestone in the joint effort to evaluate CorTec’s fully implantable closed-loop BCI platform, developed and manufactured entirely in Germany, for therapeutic applications in neurological disorders.

This second procedure took place in early February at Harborview Medical Center (Seattle) under an FDA Investigational Device Exemption (IDE). Led by Principal Investigator Jeffrey G. Ojemann, MD, from the University of Washington School of Medicine in Seattle and Co PI Professor Steven C. Cramer from the University of California, Los Angeles, the trial gathers initial safety data and evaluates whether direct cortical electrical stimulation can enhance upper-limb motor recovery in stroke patients. The study is funded by the National Institutes of Health (NIH).

“The procedure went smoothly, and the participant is recovering as expected,” said Dr. Martin Schuettler, CTO of CorTec. “Having supported the implantation of our BCI system on site for a second time, it is inspiring to see how seamlessly our teams at CorTec and UW Medicine work together. This kind of clinical and technical research collaboration is essential to deliver these procedures safely. With each step, we gain important insights that strengthen our confidence in the future of this technology.”

Jeffrey G. Ojemann, MD, Vice Chair and Professor of Neurological Surgery, University of Washington School of Medicine, commented: “We are very encouraged by the outcome of this second implantation and pleased with the participant’s steady recovery. The notable rehabilitation progress and meaningful neurological gains observed in our first study participant using CorTec’s BCI system has led us to this next phase. Each procedure helps us refine safe clinical practices for this emerging neurotechnology and explore its potential to improve outcomes for patients in the future.”

With two successful surgeries completed at Harborview Medical Center, the study will enroll further participants and continue to gather neural and behavioral data. CorTec’s implantable closed-loop BCI platform is designed to continuously record and interpret neural activity with high fidelity and deliver targeted electrical stimulation in real time. This novel approach enables highly precise and personalized neurotherapeutic interventions by enhancing neuroplasticity – the brain’s ability to reorganize neural networks – and explores whether lost functions can be relearned, potentially accelerating and improving patient rehabilitation through the integration of engineering, neurophysiology, and machine learning.

“This second implantation is a milestone for our technology and the progress of our clinical program,” said Dr. Frank Desiere, CEO of CorTec. “More importantly, it brings us closer to realizing the potential of a new class of neurotherapeutic solutions that could meaningfully improve outcomes for patients with neurological conditions and lays the groundwork for the next phase of clinical and technology development.”

CorTec will continue to share updates as the study progresses, and additional insights emerge.

About CorTec

CorTec GmbH, founded in 2010 in Freiburg, Germany is a pioneer in active implantable technologies and brain-computer interface (BCI) systems. The company is an established partner for medical device development and manufacturing for advanced components and active implantable systems. Its cutting-edge technologies drive innovation across the neurotechnology landscape—enabling researchers, clinicians, and industry leaders to unlock new clinical frontiers and engineer next-generation medical devices precisely tailored to targeted therapeutic indications. At the heart of CorTec’s portfolio is the Brain Interchange^TM System, a fully implantable, wireless investigational device capable of long-term sensing and adaptive stimulation of neural tissue. The system is designed as a versatile platform to accelerate the development of novel, personalized neuromodulation therapies and BCI applications. CorTec’s growth is supported by a strong network of strategic investors, including High-Tech Gruenderfonds, KfW, K&SW Invest, LBBW Venture Capital, Mangold Invest, M-Invest and Santo Venture Capital GmbH. Visit us on LinkedIn or at www.cortec-neuro.com.

Disclaimer: The research reported in this publication is supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Number UH3NS121565. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism

•   In the study, [68Ga]Ga-Pentixafor PET/CT was well tolerated and demonstrated high specificity and moderate sensitivity for identifying unilateral aldosterone-producing adenomas compared with adrenal vein sampling (AVS) and surgical outcomes

•  The data strengthens the clinical foundation for Phase 3 development and support the role of molecular imaging in guiding treatment decisions in the population with hypertension and underlying primary aldosteronism

Berlin, Germany – February 5, 2026 – Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), an advanced clinical-stage biotech developing novel radiopharmaceuticals, today announced publication of new Phase 2 clinical data in the Journal of Nuclear Medicine demonstrating the potential of [68Ga]Ga-Pentixafor PET/CT as a non-invasive imaging tool for subtyping primary aldosteronism (PA), the leading endocrine cause of hypertension.

The investigator-initiated study, funded by an Australian philanthropic foundation, the CASS Foundation, and the Medical Research Future Fund, was conducted as a prospective cohort study in Australia. It evaluated [68Ga]Ga-Pentixafor PET/CT as a potential alternative to adrenal vein sampling (AVS), the current standard of care for distinguishing unilateral aldosterone-producing adrenal adenomas from bilateral disease. AVS is invasive, resource-intensive, and available only in highly specialized centers, creating barriers to timely and accurate patient stratification.

Results published online show that [68Ga]Ga-Pentixafor PET/CT demonstrated high specificity and moderate sensitivity for identifying unilateral aldosterone-producing adenomas when compared with AVS and surgical outcomes. Importantly, the imaging approach was well tolerated and strongly preferred by patients, with 28 of 29 participants indicating PET/CT as the favoured diagnostic test.

“These data provide evidence that molecular imaging with [68Ga]Ga-Pentixafor PET/CT can support accurate and patient-friendly subtyping of primary aldosteronism,” said Dr. Elisabeth Ng, of the Hudson Institute of Medical Research and the Endocrinology Unit at Monash Health, the lead investigator of the study. “The high specificity observed is particularly relevant for identifying patients who may benefit from curative surgery, while the strong patient preference for PET/CT highlights the potential to expand access to and acceptance of diagnostic testing for patients with primary aldosteronism.”

The study recruited adults with primary aldosteronism and an adrenal adenoma visible on CT imaging. Diagnostic performance was assessed by comparing PET-derived lateralisation indices with AVS results and biochemical outcomes following adrenalectomy. The findings support the clinical utility of [68Ga]Ga-Pentixafor PET/CT as a noninvasive decision-support tool for identifying patients who may benefit from curative surgery.

“This published data builds on earlier investigator-initiated studies, including the CASTUS Step 1 trial and demonstrates reproducible performance across independent studies and geographies. Together, these data strengthen the clinical foundation of Pentixapharm’s primary aldosteronism program and support readiness for Phase 3 development,” said Dirk Pleimes, CEO and CMO of Pentixapharm. “Here, at Pentixapharm, we are continuing to advance our clinical and regulatory strategy for primary aldosteronism while engaging with investigators, regulators, and potential partners to maximise the clinical and commercial impact of our  molecular imaging platform.”

As new therapeutic options, including aldosterone synthase inhibitors, are expected to enter the treatment resistant hypertension market, accurate and scalable subtyping of primary aldosteronism is becoming increasingly important. Noninvasive imaging solutions may play a critical role in guiding treatment decisions and optimising patient outcomes in this evolving therapeutic landscape.

The full article, titled “Identification of Aldosterone-Producing Adrenal Adenomas Using [68Ga]Ga-Pentixafor PET/CT in an Australian Cohort,” is available in the Journal of Nuclear Medicine.

About ⁶⁸Ga-PentixaFor in treatment-resistant hypertension and primary aldosteronism

[⁶⁸Ga]Ga-PentixaFor is a novel gallium-68-labeled radiodiagnostic designed to selectively target and visualize the chemokine receptor CXCR4 using high-resolution PET/CT imaging. Clinical experience with [⁶⁸Ga]Ga-PentixaFor PET/CT in approximately 1,600 patients across different indications has demonstrated its ability to non-invasively image CXCR4 expression in vivo.

Recent research has shown strong CXCR4 overexpression in aldosterone-producing adrenal tumors, a hallmark of unilateral primary aldosteronism. Primary aldosteronism is a common but historically underdiagnosed cause of secondary hypertension, largely because reliably distinguishing unilateral from bilateral disease remains challenging with current diagnostic tools. Unilateral disease is typically treated by surgical removal of the affected adrenal gland whereas bilateral disease requires life-long medical therapy. By visualizing CXCR4 expression in aldosterone-producing tissue, [⁶⁸Ga]Ga-PentixaFor has the potential to support more reliable subtyping of primary aldosteronism and thereby better guide appropriate treatment decisions.

About the prospective phase 2 pilot study

The prospective pilot study recruited adults with PA and an adrenal adenoma visible on CT and evaluated 68Ga-Pentixafor PET/CT as a noninvasive nuclear imaging alternative to AVS, assessing its diagnostic accuracy and acceptability compared with AVS in a multiethnic population.  PentixaFor was supplied by Pentixapharm AG. The study was published in the Journal of Nuclear Medicine (JNM), which is a top-ranked peer-reviewed publication covering molecular imaging, PET/CT, and theranostics [Ng E, Jong I, Lau KK, Akram M, Morgan J, Nelva P, Simpson I, Haskali MB, Fuller PJ, Shen J, Yang J. Identification of Aldosterone-Producing Adrenal Adenomas Using [⁶⁸Ga]Ga-Pentixafor PET/CT in an Australian Cohort. J Nucl Med. 2026 Jan 29:jnumed.125.271006. (doi: 10.2967/jnumed.125.271006. Epub ahead of print. PMID: 41611475].

About Pentixapharm

Pentixapharm is an advanced clinical-stage biotech expanding the boundaries of radiopharmaceuticals. Headquartered in Berlin, Germany, the company develops precision diagnostics and therapeutics in oncology and cardiology to transform patient care. Its clinical pipeline is anchored by CXCR4-targeted PET-CT programs, including a Phase 3-ready candidate for the improved diagnosis of hypertensive patients with primary aldosteronism, which is intended to enable targeted treatment of the underlying causes of hypertension. CXCR4-based developments also include pioneering therapeutic programs in hematological cancers. Furthermore, Pentixapharm is advancing a next-generation antibody platform targeting CD24, an emerging immune-checkpoint marker over-expressed in multiple hard-to-treat cancers. Complemented by CXCR4 and CD24 intellectual property protection and a reliable isotope supply chain, Pentixapharm is poised to deliver meaningful patient benefit and sustainable growth in one of the fastest-growing areas of precision medicine.

Pentixapharm Investor and Media Contact

ir@pentixapharm.com